Breaking News

Pharma still 'falling short' in providing access to low- and middle-income countries, analysis finds

November 19, 2024
Pharmalot Columnist, Senior Writer
Adobe

STAT+ | Pharma still 'falling short' in providing access to low- and middle-income countries, analysis finds

A new analysis found the few companies with programs for improving access in poor countries largely fail to report how many patients are being reached.

By Ed Silverman


STAT+ | Merck says study of under-the-skin version of Keytruda, a bid to extend the drug's sales, succeeded

The new formulation could help secure a larger share of the blockbuster's sales after the cancer drug's U.S. patent expires in 2028.

By Matthew Herper


STAT+ | With RFK Jr. looming as health secretary, pharma execs try to project stability

While RFK Jr. has been a vocal critic of pharma, BioNTech and Bristol Myers Squibb execs sought to project calm about Trump's pick for HHS.

By Andrew Joseph



Adobe

Opinion: The FDA's risky action on compounding weight loss drugs

High-quality manufactured drugs should not become products that only certain patients can afford, writes former FDA Commissioner Scott Gottlieb.

By Scott Gottlieb


The many legal fronts of RFK Jr.'s fight against vaccines

Kennedy's nonprofit, Children's Health Defense, is involved in vaccine lawsuits against agencies he could wind up overseeing

By Isabella Cueto


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments